Novartis AG’s efforts to re-envision clinical development with the same focus on “disruptive innovation” that produced the Novartis Institutes for BioMedical Research Inc. a decade ago were a theme throughout presentations at the company’s R&D Investor Day in Boston Nov. 8.
Novartis Brings “Disruptive Innovation” To Clinical Trials
Having reinvigorated its model for early R&D, the company is looking to re-envision the clinical trial process, with initiatives aimed at improving patient selection based on molecular information, clinical trial recruitment and monitoring. A partnership with Walgreens aims to move trials out of tertiary care centers and into pharmacies.